Renormalization-group theory stands, since over 40 years, as one of the pillars of modern physics. As such, there should be no remaining doubt regarding its validity. However, finite-size scaling, which derives from it, has long been poorly understood above the upper critical dimension d c in models with free boundary conditions. Besides its fundamental significance for scaling theories, the issue is important at a practical level because finite-size, statistical-physics systems, with free boundaries above d c , are experimentally accessible with long-range interactions. Here we address the roles played by Fourier modes for such systems
The correlation length plays a pivotal role in finite-size scaling and hyperscaling at continuous phase transitions. Below the upper critical dimension, where the correlation length is proportional to the system length, both finite-size scaling and hyperscaling take conventional forms. Above the upper critical dimension these forms break down and a new scaling scenario appears. Here we investigate this scaling behaviour by simulating one-dimensional Ising ferromagnets with long-range interactions. We show that the correlation length scales as a non-trivial power of the linear system size and investigate the scaling forms. For interactions of sufficiently long range, the disparity between the correlation length and the system length can be made arbitrarily large, while maintaining the new scaling scenarios. We also investigate the behavior of the correlation function above the upper critical dimension and the modifications imposed by the new scaling scenario onto the associated Fisher relation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.